Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Marnix Wieffer
Drug Safety Information Specialist
About the author:
As drug safety information specialist, I support pharmaceutical companies in identifying potential drug toxicity concerns and adverse effects. During my first 3 years at Elsevier, I have been working with both academic and corporate customers in northern Europe. As senior marketing manager, I am currently responsible for Elsevier’s drug safety messaging, internal training and market engagement.
Posts by Marnix Wieffer
PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator
Posted on December 11th, 2019 in Pharma R&D
When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.
(more…)FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool
Posted on December 3rd, 2019 in Pharma R&D
A leading cause of attrition of compounds in drug development, drug-induced liver injury (DILI) is also one of the top causes of drug withdrawals, restrictions and project terminations. DILI results when reactive metabolites – formed when certain orally administered drugs are metabolized in the liver – end up binding to cellular proteins and damaging liver cells.
(more…)Making better drug development decisions with extracted preclinical and clinical data
Posted on June 12th, 2019 in Pharma R&D
Improving the speed and ease of collecting pharmacovigilance data
Posted on June 12th, 2019 in Pharma R&D
Learn how the staff of biotechnology company 4P-Pharma uses Elsevier’s Embase to address challenges in conducting clinical trials.
(more…)
